BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic ...

An analysis of key drug trials for psoriatic arthritis shows geographic disparities and racial gaps; most participants have ...

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

Enthesitis is a key, but often overlooked, feature of psoriatic arthritis. Learn how this inflammation at tendon and ligament attachment sites can affect diagnosis, symptoms, and treatment.

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

The following is a summary of “Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal ...

EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more ...

European researchers unveil digital tools and explainable AI that personalize psoriatic arthritis care, enabling early ...

Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...